NCT01400828已完成3 期
Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With Seasonal Allergic Rhinitis
Yuhan Corporation1 个研究点 分布在 1 个国家目标入组 239 人开始时间: 2011年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 239
- 试验地点
- 1
- 主要终点
- AUC of TSS
研究概览
简要总结
The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 12 Years 至 70 Years（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular redness), as well as the skin prick test performed at the time of selection or within the year prior to entering.
- •Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and symptoms were included if they were between 12 and 70 years old, gave their informed consent, attended the required visits scheduled and also underwent a complete medical examination..
排除标准
- •Patients were excluded if they had a significant nasal abnormality which could interfere with the aim of the study, acute or chronic sinusitis, asthma or any condition, disease or hypersensitivity that could be harmed.
- •Patients were not allowed to take forbidden medications or not comply the study requirements.
- •Patients who were currently participating in or had participated in another clinical trial within the previous three months or were planning to travel outside of the study area during the course of the study were excluded.
- •Pregnant or breast-feeding women were also excluded.
- •Women of childbearing potential had a pregnancy test done
研究组 & 干预措施
Bilastine
Experimental
Intervention: Drug: Bilastine
干预措施: Bilastine (Drug)
Desloratadine
Active Comparator
Intervention: Drug: Desloratadine
干预措施: Desloratadine (Drug)
Placebo
Placebo Comparator
Intervention: Drug: Placebo
干预措施: Placebo (Drug)
结局指标
主要结局
AUC of TSS
时间窗: 14 days
The area under curve (AUC) of the total symptom score (TSS) since basal visit to D14 visit according to the patient's assessment
次要结局
- Change in total nasal symptom score (TNSS)(14 days)
- •Change in total non-nasal symptom score (TNNSS)(14 days)
- safety assessment(14 days)
- responde's rate(14 days)
- Change in TSS. Reflective symptoms(14 days)
- Change in TSS. Instantaneous score(14days)
- VAS of discomfort(14 days)
- •Allergic rhinitis (AR) quality of life (QoL) questionnaire (RQLQ)(14 days)
- CGI(14 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With BilastineSeasonal Allergic RhinitisNCT01108783Faes Farma, S.A.720
已完成
3 期
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic UrticariaUrticariaNCT00421109Faes Farma, S.A.522
已完成
3 期
Efficacy Study for the Symptomatic Treatment of Seasonal Allergic RhinitisSeasonal Allergic RhinitisNCT00504933Faes Farma, S.A.683
已完成
2 期
PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm)Seasonal Allergic RhinitisHay FeverRhinoconjunctivitisNCT00574210Faes Farma, S.A.502
已完成
1 期
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of BilastineHealthyNCT00419783Faes Farma, S.A.30